Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

Anxiety Disorders Clinical Trial

Official title:

Flourishing and Virtue in Cognitive-Behavioral Therapy for Anxiety and Depressive Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05120232
• Other study ID #: 61245
• Secondary ID: 5724E
• Status: Recruiting
• Phase: N/A
• Start date: March 8, 2021
• Est. completion date: July 1, 2023

Study information

• Verified date: January 2023
• Source: Boston University Charles River Campus
• Contact: Todd Farchione, Ph.D.
• Phone: 617-353-9609
• Email: tfarchio[@]bu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This two phase study is testing an online version of a transdiagnostic, cognitive behavioral therapy, against a modified version of that therapy emphasizing positive affect. The first phase of the trial will focus on content development for the modified therapy and the second phase will be a randomized control trial comparing the two.

Description:

Research shows that positive emotions can buffer against the effects of stress as well as contribute to overall well-being and functioning. People with emotional disorders, such as anxiety and depression, often report lower levels of positive emotions. However, to date, most existing treatment approaches for emotional disorders focus on regulating negative emotions, without explicitly focusing on positive emotions. The Unified Protocol (UP) is a transdiagnostic, cognitive-behavioral therapy that has been shown to be effective for treating emotional disorders. The UP targets negative emotions and helps people respond to their emotions in ways that are more helpful for them and in line with their goals. In its current form, the UP does not explicitly target positive emotions, but some research suggests that individuals treated with the UP and other cognitive-behavioral treatments experience some improvement in positive affect. In the current study, the researchers will create a modified version of the UP (called the UP+) delivered entirely on an online platform that will include exercises specifically designed to enhance positive emotions. Then, the researchers will evaluate the UP+ in a small sample of participants to examine acceptability and feasibility and will then use this information to continue to refine the protocol. Finally, the researchers will conduct a randomized controlled trial to assess the efficacy of the UP+. Participants diagnosed with emotional disorders will be randomized to either receive the UP or the UP+ delivered on an online platform and will be assessed on a range of outcomes, including positive and negative affect, psychological symptoms, and functional outcomes.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 125
• Est. completion date: July 1, 2023
• Est. primary completion date: July 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Diagnosed with a DSM-5 anxiety, obsessive-compulsive, or depressive disorder Exclusion Criteria: Acute risk factors (suicidal or homicidal ideation or clinical condition requiring immediate treatment); The individual is in treatment elsewhere for related issues; and/or The individual is considering changing their treatment and and/or psychotropic medication during the time period in which they would be enrolled in the study and/or The individual is unable or unwilling to commit to the study procedures.

Related Conditions & MeSH terms

• Anxiety Disorders
• Depression
• Depressive Disorder
• Disease

Intervention

Behavioral:
• Unified Protocol
A transdiagnostic, cognitive behavioral therapy.
• Modified Unified Protocol (UP+)
A transdiagnostic, cognitive behavioral therapy.

Locations

Country	Name	City	State
United States	Center for Anxiety and Related Disorders - Boston University	Boston	Massachusetts

Sponsors (3)

Lead Sponsor	Collaborator
Boston University Charles River Campus	Harvard School of Public Health (HSPH), University of Kentucky

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Positive and Negative Affect Schedule Expanded Form (PANAS-X) Score	The PANAS-X is a brief, reliable and valid measure of positive and negative affect. It consists of 20 feeling or emotion words (e.g., interested, upset, nervous). Respondents rate each emotion word on a scale ranging from 1 = very slightly or not at all to 5 = extremely, indicating the extent to which they experience that emotion or feeling in general. The PANAS-X has shown excellent convergent and discriminant correlations with lengthier measures of underlying mood factors and is a widely used measure of state negative affect (Watson et al., 1988).	Baseline, every week through 12-weeks following baseline, 3 months following the treatment phase
Other	Change in Savoring Beliefs Inventory (SBI) Score	The SBI is a measure of one's tendency to savor or dampen positive emotions (Bryant, F. B. 2003). It includes distinctions among future, present, and past focused forms of savouring. The SBI includes 24 items with 4 positively-worded and 4 negatively-worded items for each of the three temporal forms of savoring (rated on a 7-point scale from 1 = strongly agree to 7 = strongly disagree) . Overall, the SBI is a valid and reliable measure of individuals' beliefs about their capacity to savour positive experiences (Bryant 2003).	Baseline, every week through 12-weeks following baseline, 3 months following the treatment phase
Other	Change in Flourish Index (FI) Score	The FI is a measurement approach to human flourishing, based around five central domains: happiness and life satisfaction, mental and physical health, meaning and purpose, character and virtue, and close social relationships. The FI consists of 10 questions on a 10 point Likert scale (with 0 = strongly disagree to 10 = strongly agree) (VanderWeele, 2017). The FI has demonstrated good internal consistency and evidence of validity and reliability (We?ziak-Bialowolska et al, 2019).	Baseline, every week through 12-weeks following baseline, 3 months following the treatment phase
Primary	Change in Anxiety and Related Disorders Interview Schedule for Diagnostic and Statistical Manual-5 (ADIS-5) Score	This semi-structured, diagnostic clinical interview focuses on Diagnostic and Statistical Manual-5 diagnoses of anxiety disorders and their accompanying mood states, somatoform disorders, and substance and alcohol use. The information derived from the interview using the ADIS allows clinicians to determine differential diagnoses and gain a clear understanding of the level and severity of each diagnosis. Principal and additional diagnoses are assigned a clinical severity rating (CSR) on a scale from 0 (no symptoms) to 8 (extremely severe symptoms), with a rating of 4 or above (definitely disturbing/disabling) passing the clinical threshold for DSM diagnostic criteria. Inquiries about suicidal ideation are part of this interview. This measure has demonstrated excellent to acceptable interrater reliability for the anxiety and mood disorders (Brown, Di Nardo, et al., 2001).	Baseline, 12-weeks following baseline, 3 months following the treatment phase